Follow Denali Therapeutics to never miss an important update.
Denali reported its second full quarter of sales for Avlayah, its first approved drug for Hunter syndrome. Revenue reached nearly $18 million, and management expects that to nearly double next quarter. This growth is a critical test for the company's technology, which is designed to carry medicines across the blood-brain barrier, a protective layer that usually blocks drugs from reaching the brain.
The company reported a profit of $70 million this quarter, though this was largely due to a one-time $194 million gain from selling a regulatory voucher. This sale helped Denali maintain a $1 billion cash cushion, which is vital for a biotech company that is still spending heavily to develop its next four drugs for rare brain diseases.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
The Galien Foundation, an organization that honors medical innovation, awarded Avlayah its top prize for biotechnology. The award highlights the drug's role as the first approved biologic designed to cross the blood-brain barrier. While such awards do not directly impact sales, they help validate Denali's delivery technology as it prepares to submit its second drug for approval next year.
Source: GlobeNewsWire
Management has a long history of setting conservative targets and clearing them by small margins. This latest quarter shows the business is starting to outrun those forecasts as its first drug launch gains real speed.
| Expectation | |
|---|---|
| EPS | $-0.64 |
| Revenue | $32M |
Follow Denali Therapeutics to get the latest and most important updates.
Follow DNLI